Dr. Anwaar Saeed
Claim this profileUniversity of Kansas Cancer Center
Studies Colorectal Cancer
Studies Liver Cancer
20 reported clinical trials
37 drugs studied
Area of expertise
1Colorectal Cancer
Stage IV
Stage III
PD-L1 positive
2Liver Cancer
Stage III
Stage IV
RAF positive
Affiliated Hospitals
Clinical Trials Anwaar Saeed is currently running
Tisotumab Vedotin
for Cancer
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur. There are seven parts to this study. * In Part A, the treatment will be given to participants every 3 weeks (3-week cycles). * In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle. * In Part C, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part D, participants will be given treatment on Day 1 of every 3-week cycle. Participants in Part D will get tisotumab vedotin with either: * Pembrolizumab or, * Pembrolizumab and carboplatin, or * Pembrolizumab and cisplatin * In Part E, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part F, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part F will get tisotumab vedotin with pembrolizumab. * In Part G, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part G will get tisotumab vedotin with pembrolizumab and carboplatin.
Recruiting1 award Phase 216 criteria
OBT076
for Advanced Cancer
The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to target cancer cells and deliver an anti-cancer drug. OBT076 is composed of an antibody that targets the CD205 protein on cancer cells and delivers an anti-cancer drug which can kill them. OBT076 is an "Investigational Drug", which means that it is still being studied and has not yet been approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory authorities to be prescribed by doctors for the treatment of metastatic or recurrent solid tumors. The use of OBT076 in this study is investigational. This is a Phase I research study designed to look at several dose levels of the study drug to find the highest dose level that is safe and well-tolerated (does not cause unacceptable side effects), and to examine the effects of the study drug in a small group of research participants. The study will also look at the effectiveness of OBT076 as an anti-cancer therapy. Once the optimal dose is determined and safety is assessed, additional research participants will be treated at the optimal dose level to further evaluate safety and effectiveness.
Recruiting1 award Phase 115 criteria
More about Anwaar Saeed
Clinical Trial Related2 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Anwaar Saeed has experience with
- Atezolizumab
- Durvalumab
- Oxaliplatin
- Tremelimumab
- 9-ING-41
- Gemcitabine
Breakdown of trials Anwaar Saeed has run
Colorectal Cancer
Liver Cancer
Gastroesophageal Junction Adenocarcinoma
Skin Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Anwaar Saeed specialize in?
Anwaar Saeed focuses on Colorectal Cancer and Liver Cancer. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are Stage III.
Is Anwaar Saeed currently recruiting for clinical trials?
Yes, Anwaar Saeed is currently recruiting for 10 clinical trials in Westwood Kansas. If you're interested in participating, you should apply.
Are there any treatments that Anwaar Saeed has studied deeply?
Yes, Anwaar Saeed has studied treatments such as Atezolizumab, Durvalumab, Oxaliplatin.
What is the best way to schedule an appointment with Anwaar Saeed?
Apply for one of the trials that Anwaar Saeed is conducting.
What is the office address of Anwaar Saeed?
The office of Anwaar Saeed is located at: University of Kansas Cancer Center, Westwood, Kansas 66205 United States. This is the address for their practice at the University of Kansas Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.